Rinvoq passes PhIII maintenance study for Crohn's disease, potentially setting the stage for label expansion
After AbbVie’s Rinvoq first got approved back in 2019, JAK inhibitors have been clouded by numerous safety issues and events, like with rival Pfizer’s Xeljanz …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
